Returning to its roots, Amgen adding growth with $28.7B deal for Horizon 

With sales flat and its push into cancer yet to yield any major growth drivers, Amgen’s $28.7 billion acquisition of Horizon Therapeutics marks a continuation of the large cap’s return to the inflammatory and autoimmune space where it’s been most commercially successful.

The deal is also the latest — and largest — move by Amgen Inc. (NASDAQ:AMGN) to add growth via acquisitions...